Abacavir

Last updated

Abacavir
Abacavir.svg
Abacavir ball-and-stick model.png
Chemical structure of abacavir
Clinical data
Pronunciation /əˈbækəvɪər/ ⓘ
Trade names Ziagen
Other namesAbacavir sulfate (USAN US)
AHFS/Drugs.com Monograph
MedlinePlus a699012
License data
Pregnancy
category
  • AU:B3
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 83%
Metabolism Liver
Elimination half-life 1.54 ± 0.63 h
Excretion Kidney (1.2% abacavir, 30% 5'-carboxylic acid metabolite, 36% 5'-glucuronide metabolite, 15% unidentified minor metabolites). Fecal (16%)
Identifiers
  • {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard 100.149.341 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C14H18N6O
Molar mass 286.339 g·mol−1
3D model (JSmol)
Melting point 165 °C (329 °F)
  • n3c1c(ncn1[C@H]2/C=C\[C@@H](CO)C2)c(nc3N)NC4CC4
  • InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1 Yes check.svgY
  • Key:MCGSCOLBFJQGHM-SCZZXKLOSA-N Yes check.svgY
   (verify)

Abacavir, sold under the brand name Ziagen among others, is a medication used to treat HIV/AIDS. [3] [4] [5] [6] Similar to other nucleoside analog reverse-transcriptase inhibitors (NRTIs), abacavir is used together with other HIV medications, and is not recommended by itself. [7] It is taken by mouth as a tablet or solution and may be used in children over the age of three months. [5] [8]

Contents

Abacavir is generally well tolerated. [8] Common side effects include vomiting, insomnia (trouble sleeping), fever, and feeling tired. [5] Other common side effects include loss of appetite, headache, nausea (feeling sick), diarrhea, rash, and lethargy (lack of energy). [4] More severe side effects include hypersensitivity, liver damage, and lactic acidosis. [5] Genetic testing can indicate whether a person is at higher risk of developing hypersensitivity. [5] Symptoms of hypersensitivity include rash, vomiting, and shortness of breath. [8] Abacavir is in the NRTI class of medications, which work by blocking reverse transcriptase, an enzyme needed for HIV virus replication. [9] Within the NRTI class, abacavir is a carbocyclic nucleoside. [5]

Abacavir was patented in 1988, and approved for use in the United States in 1998. [10] [11] It is on the World Health Organization's List of Essential Medicines. [12] It is available as a generic medication. [5] Abacavir is used together with other HIV medications, such as abacavir/lamivudine/zidovudine, abacavir/dolutegravir/lamivudine, and abacavir/lamivudine. [8] [9] The combination abacavir/lamivudine is an essential medicine. [12]

Medical uses

Abacavir, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection. [3] [4] Abacavir should be used in combination with other antiretroviral agents. [3] [4]

Contraindications

Abacavir is contraindicated for people who have the HLA‑B*5701 allele or who have moderate or severe liver disease (hepatic impairment). [3] [4]

Side effects

Common adverse reactions include nausea, headache, fatigue, vomiting, diarrhea, Anorexia (symptom) (loss of appetite), and insomnia (trouble sleeping). Rare but serious side effects include hypersensitivity reaction such as rash, elevated AST and ALT, depression, anxiety, fever/chills, URI, lactic acidosis, hypertriglyceridemia, and lipodystrophy. [13]

Hypersensitivity syndrome

Hypersensitivity to abacavir is strongly associated with a specific allele at the human leukocyte antigen B locus namely HLA-B*5701. [14] [15] [16] The mechanism for this hypersensitivity reaction is due to abacavir binding in the antigen-binding cleft of HLA-B*57:01, allowing alternative peptides to bind, which appear as "non-self" when presented to T cells. [17] There is an association between the prevalence of HLA-B*5701 and ancestry. The prevalence of the allele is estimated to be 3.4 to 5.8 percent on average in populations of European ancestry, 17.6 percent in Indian Americans, 3.0 percent in Hispanic Americans, and 1.2 percent in Chinese Americans. [18] [19] There is significant variability in the prevalence of HLA-B*5701 among African populations. In African Americans, the prevalence is estimated to be 1.0 percent on average, 0 percent in the Yoruba from Nigeria, 3.3 percent in the Luhya from Kenya, and 13.6 percent in the Masai from Kenya, although the average values are derived from highly variable frequencies within sample groups. [20]

Common symptoms of abacavir hypersensitivity syndrome include fever, malaise, nausea, and diarrhea. Some patients may also develop a skin rash. [21] Symptoms of AHS typically manifest within six weeks of treatment using abacavir, although they may be confused with symptoms of HIV, immune reconstitution syndrome, hypersensitivity syndromes associated with other drugs, or infection. [22] The U.S. Food and Drug Administration (FDA) released an alert concerning abacavir and abacavir-containing medications on 24 July 2008, [23] and the FDA-approved drug label for abacavir recommends pre-therapy screening for the HLA-B*5701 allele and the use of alternative therapy in subjects with this allele. [3] Additionally, both the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group recommend use of an alternative therapy in individuals with the HLA-B*5701 allele. [24] [25]

Patch test Epikutanni-test.jpg
Patch test

Skin-patch testing may also be used to determine whether an individual will experience a hypersensitivity reaction to abacavir, although some patients susceptible to developing AHS may not react to the patch test. [26]

The development of suspected hypersensitivity reactions to abacavir requires immediate and permanent discontinuation of abacavir therapy in all patients, including patients who do not possess the HLA-B*5701 allele. On 1 March 2011, the FDA informed the public about an ongoing safety review of abacavir and a possible increased risk of heart attack associated with the drug. [27] A meta-analysis of 26 studies conducted by the FDA, however, did not find any association between abacavir use and heart attack [28] [29]

Immunopathogenesis

The mechanism underlying abacavir hypersensitivity syndrome is related to the change in the HLA-B*5701 protein product. Abacavir binds with high specificity to the HLA-B*5701 protein, changing the shape and chemistry of the antigen-binding cleft. This results in a change in immunological tolerance and the subsequent activation of abacavir-specific cytotoxic T cells, which produce a systemic reaction known as abacavir hypersensitivity syndrome. [17]

Interaction

Abacavir, and in general NRTIs, do not undergo hepatic metabolism and therefore have very limited (to none) interaction with the CYP enzymes and drugs that effect these enzymes. That being said there are still few interactions that can affect the absorption or the availability of abacavir. Below are few of the common established drug and food interaction that can take place during abacavir co-administration:

Mechanism of action

Abacavir is a nucleoside reverse transcriptase inhibitor that inhibits viral replication. It is a guanosine analogue that is phosphorylated to carbovir triphosphate (CBV-TP). CBV-TP competes with the viral molecules and is incorporated into the viral DNA. Once CBV-TP is integrated into the viral DNA, transcription and HIV reverse transcriptase is inhibited. [37]

Pharmacokinetics

Abacavir is given orally and is rapidly absorbed with a high bioavailability of 83%. [38] Solution and tablet have comparable concentrations and bioavailability. Abacavir can be taken with or without food. [39]

Abacavir can cross the blood–brain barrier. Abacavir is metabolized primarily through the enzymes alcohol dehydrogenase and glucuronyl transferase to an inactive carboxylate and glucuronide metabolites. It has a half-life of approximately 1.5-2.0 hours. If a person has liver failure, abacavir's half life is increased by 58%. [40]

Abacavir is eliminated via excretion in the urine (83%) and feces (16%). [41] It is unclear whether abacavir can be removed by hemodialysis or peritoneal dialysis. [37]

History

Robert Vince and Susan Daluge along with Mei Hua, a visiting scientist from China, developed the medication in the '80s. [42] [43] [44]

Abacavir was approved by the U.S. Food and Drug Administration (FDA) on 18 December 1998, and is thus the fifteenth approved antiretroviral drug in the United States. [45] Its patent expired in the United States on 26 December 2009.[ citation needed ]

Synthesis

Abacavir synthesis: Abacavir synthesis.png
Abacavir synthesis:

Related Research Articles

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses.

<span class="mw-page-title-main">Zalcitabine</span> Chemical compound

Zalcitabine, also called dideoxycytidine, is a nucleoside analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen.

<span class="mw-page-title-main">Lamivudine</span> Chemical compound

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

<span class="mw-page-title-main">Entecavir</span> Chemical compound

Entecavir (ETV), sold under the brand name Baraclude, is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection. In those with both HIV/AIDS and HBV antiretroviral medication should also be used. Entecavir is taken by mouth as a tablet or solution.

<span class="mw-page-title-main">Efavirenz</span> Antiretroviral medication

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth.

<span class="mw-page-title-main">Abacavir/lamivudine/zidovudine</span> Mixture of chemical compounds

Abacavir/lamivudine/zidovudine, sold under the brand name Trizivir, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:

<span class="mw-page-title-main">Lamivudine/zidovudine</span> Combination drug for HIV

Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains two antiretroviral medications, lamivudine and zidovudine. It is used together with other antiretrovirals. It is taken by mouth twice a day.

<span class="mw-page-title-main">Raltegravir</span> Chemical compound

Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.

<span class="mw-page-title-main">Abacavir/lamivudine</span> Combination drug for HIV

Abacavir/lamivudine, sold under the brand name Kivexa among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains abacavir and lamivudine. It is generally recommended for use with other antiretrovirals. It is commonly used as part of the preferred treatment in children. It is taken by mouth as a tablet.

<span class="mw-page-title-main">Elvucitabine</span> Medication

Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection.

<span class="mw-page-title-main">HLA-B57</span>

HLA-B57 (B57) is an HLA-B serotype. B57 is a split antigen from the B17 broad antigen, the sister serotype B58. The serotype identifies the more common HLA-B*58 gene products. Like B58, B57 is involved in drug-induced inflammatory skin disorders.

<span class="mw-page-title-main">HIV disease–related drug reaction</span>

HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.

ViiV Healthcare is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS, with global headquarters in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company. In 2012 Shionogi joined the company. 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi. According to The Financial Times, the company’s coownership structure may change depending upon the achievement of certain milestones.

Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors began in the 1980s when the AIDS epidemic hit Western societies. NRTIs inhibit the reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of the human immunodeficiency virus (HIV). The first NRTI was zidovudine, approved by the U.S. Food and Drug Administration (FDA) in 1987, which was the first step towards treatment of HIV. Six NRTI agents and one NtRTI have followed. The NRTIs and the NtRTI are analogues of endogenous 2´-deoxy-nucleoside and nucleotide. Drug-resistant viruses are an inevitable consequence of prolonged exposure of HIV-1 to anti-HIV drugs.

<span class="mw-page-title-main">Abacavir/dolutegravir/lamivudine</span> Drug combination for HIV

Abacavir/dolutegravir/lamivudine, sold under the brand name Triumeq among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: abacavir, dolutegravir and lamivudine.

Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains dolutegravir, as the salt, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is taken by mouth.

<span class="mw-page-title-main">Elsulfavirine</span> Chemical compound

Elsulfavirine is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine. It was developed by the Russian company Viriom.

References

  1. ↑ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 24 March 2022. Retrieved 23 August 2022.
  2. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  3. 1 2 3 4 5 6 "Ziagen- abacavir sulfate tablet, film coated label". DailyMed. 30 September 2015. Archived from the original on 11 January 2017. Retrieved 9 September 2019.
  4. 1 2 3 4 5 6 "Ziagen EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 30 July 2022. Retrieved 22 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. 1 2 3 4 5 6 7 "Abacavir Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 21 August 2017. Retrieved 31 July 2015.
  6. ↑ "Drug Name Abbreviations Adult and Adolescent ARV Guidelines". AIDSinfo. Archived from the original on 9 November 2016. Retrieved 8 November 2016.
  7. ↑ "What Not to Use Adult and Adolescent ARV Guidelines". AIDSinfo. Archived from the original on 9 November 2016. Retrieved 8 November 2016.
  8. 1 2 3 4 Yuen GJ, Weller S, Pakes GE (2008). "A review of the pharmacokinetics of abacavir". Clinical Pharmacokinetics. 47 (6): 351–371. doi:10.2165/00003088-200847060-00001. PMID   18479171. S2CID   31107341.
  9. 1 2 "Nucleoside reverse transcriptase inhibitors (NRTIs or 'nukes') - HIV/AIDS". www.hiv.va.gov. Archived from the original on 9 November 2016. Retrieved 8 November 2016.
  10. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 505. ISBN   9783527607495. Archived from the original on 8 September 2017.
  11. ↑ Kane BM (2008). HIV/AIDS Treatment Drugs. Infobase Publishing. p. 56. ISBN   9781438102078. Archived from the original on 8 September 2017.
  12. 1 2 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  13. ↑ "Abacavir Adverse Reactions". Epocrates Online. Archived from the original on 23 August 2021. Retrieved 9 November 2012.
  14. ↑ Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. (February 2008). "HLA-B*5701 screening for hypersensitivity to abacavir". The New England Journal of Medicine. 358 (6): 568–579. doi: 10.1056/nejmoa0706135 . PMID   18256392. Archived from the original on 22 January 2021. Retrieved 9 July 2019.
  15. ↑ Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S (July 2006). "Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study". Clinical Infectious Diseases. 43 (1): 99–102. doi: 10.1086/504874 . PMID   16758424.
  16. ↑ Dean L (2015). "Abacavir Therapy and HLA-B*57:01 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID   28520363. Bookshelf ID: NBK315783. Archived from the original on 26 October 2020. Retrieved 14 January 2019.
  17. 1 2 Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. (June 2012). "Immune self-reactivity triggered by drug-modified HLA-peptide repertoire". Nature. 486 (7404): 554–558. Bibcode:2012Natur.486..554I. doi: 10.1038/nature11147 . PMID   22722860. S2CID   4408811.
  18. ↑ Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. (March 2002). "Genetic variations in HLA-B region and hypersensitivity reactions to abacavir". Lancet. 359 (9312): 1121–1122. doi:10.1016/s0140-6736(02)08158-8. PMID   11943262. S2CID   9434238.
  19. ↑ Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. (March 2002). "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir". Lancet. 359 (9308): 727–732. doi:10.1016/s0140-6736(02)07873-x. PMID   11888582. S2CID   12923232.
  20. ↑ Rotimi CN, Jorde LB (October 2010). "Ancestry and disease in the age of genomic medicine". The New England Journal of Medicine. 363 (16): 1551–1558. doi: 10.1056/nejmra0911564 . PMID   20942671.
  21. ↑ Phillips E, Mallal S (2009). "Successful translation of pharmacogenetics into the clinic: the abacavir example". Molecular Diagnosis & Therapy. 13 (1): 1–9. doi:10.1007/bf03256308. PMID   19351209. S2CID   45896364.
  22. ↑ Phillips E, Mallal S (August 2007). "Drug hypersensitivity in HIV". Current Opinion in Allergy and Clinical Immunology. 7 (4): 324–330. doi:10.1097/aci.0b013e32825ea68a. PMID   17620824. S2CID   37549824.
  23. ↑ "Information for Healthcare Professionals: Abacavir (marketed as Ziagen) and Abacavir-Containing Medications". Food and Drug Administration (FDA). 24 July 2008. Archived from the original on 11 December 2013. Retrieved 29 November 2013.
  24. ↑ Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. (May 2011). "Pharmacogenetics: from bench to byte--an update of guidelines". Clinical Pharmacology and Therapeutics. 89 (5): 662–673. doi: 10.1038/clpt.2011.34 . PMID   21412232. S2CID   2475005.
  25. ↑ Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. (May 2014). "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update". Clinical Pharmacology and Therapeutics. 95 (5): 499–500. doi:10.1038/clpt.2014.38. PMC   3994233 . PMID   24561393.
  26. ↑ Shear NH, Milpied B, Bruynzeel DP, Phillips EJ (May 2008). "A review of drug patch testing and implications for HIV clinicians". AIDS. 22 (9): 999–1007. doi:10.1097/qad.0b013e3282f7cb60. PMID   18520343. S2CID   2972984.
  27. ↑ "FDA Drug Safety Communication: Safety Review update of Abacavir and possible increased risk of heart attack". Food and Drug Administration (FDA). 1 March 2011. Archived from the original on 13 December 2019. Retrieved 9 September 2019.
  28. ↑ "FDA Alert: Abacavir - Ongoing Safety Review: Possible Increased Risk of Heart Attack". Drugs.com. Archived from the original on 10 December 2013. Retrieved 29 November 2013.
  29. ↑ Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA (December 2012). "No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis". Journal of Acquired Immune Deficiency Syndromes. 61 (4): 441–447. doi: 10.1097/QAI.0b013e31826f993c . PMID   22932321. S2CID   7997822.
  30. 1 2 Prescribing information. Ziagen (abacavir). Research Triangle Park, NC: GlaxoSmithKline, July 2002
  31. ↑ Vourvahis M, Kashuba AD (June 2007). "Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir". Pharmacotherapy. 27 (6): 888–909. doi:10.1592/phco.27.6.888. PMID   17542771. S2CID   23591048.
  32. ↑ McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS (June 2000). "Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults". Antimicrobial Agents and Chemotherapy. 44 (6): 1686–1690. doi:10.1128/aac.44.6.1686-1690.2000. PMC   89933 . PMID   10817729.
  33. ↑ Berenguer J, Pérez-Elías MJ, Bellón JM, Knobel H, Rivas-González P, Gatell JM, et al. (February 2006). "Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort". Journal of Acquired Immune Deficiency Syndromes. 41 (2): 154–159. doi: 10.1097/01.qai.0000194231.08207.8a . PMID   16394846. S2CID   17609676.
  34. ↑ Dolophine(methadone) [prescribing information]. Columbus, OH: Roxane Laboratories, Inc.; March 2015.
  35. ↑ Gervasoni C, Cattaneo D, Di Cristo V, Castoldi S, Gervasi E, Clementi E, Riva A (June 2016). "Orlistat: weight lost at cost of HIV rebound". The Journal of Antimicrobial Chemotherapy. 71 (6): 1739–1741. doi: 10.1093/jac/dkw033 . PMID   26945709.
  36. ↑ Cometriq (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc.; May 2016.
  37. 1 2 Product Information: ZIAGEN(R) oral tablets, oral solution, abacavir sulfate oral tablets, oral solution. ViiV Healthcare (per Manufacturer), Research Triangle Park, NC, 2015.
  38. ↑ Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, Stein DS (August 1999). "Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food". Pharmacotherapy. 19 (8): 932–942. doi:10.1592/phco.19.11.932.31568. PMID   10453964. S2CID   20131476.
  39. ↑ Jones A (May 2019). "Food requirements for anti-HIV medications". aidsmap.com. Archived from the original on 25 April 2021. Retrieved 21 December 2020.
  40. ↑ Wyles DL, Gerber JG (March 2005). "Abacavir pharmacokinetics in hepatic dysfunction". Clinical Infectious Diseases. 40 (6): 909–910. doi: 10.1086/429247 . PMID   15736035.
  41. ↑ Yuen GJ, Weller S, Pakes GE (2008). "A review of the pharmacokinetics of abacavir". Clinical Pharmacokinetics. 47 (6): 351–71. doi:10.2165/00003088-200847060-00001. PMID   18479171. S2CID   31107341.
  42. ↑ "Dr. Robert Vince - 2010 Inductee". Minnesota Inventors Hall of Fame. Archived from the original on 15 February 2016. Retrieved 10 February 2016.
  43. ↑ "Robert Vince, PhD (faculty listing)". University of Minnesota. Archived from the original on 17 February 2016.
  44. ↑ Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, et al. (May 1997). "1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity". Antimicrobial Agents and Chemotherapy. 41 (5): 1082–1093. doi:10.1128/AAC.41.5.1082. PMC   163855 . PMID   9145874.
  45. ↑ Mary Annette Banach. "How HIV Clinicians Acquire Representational Fluency: A Case Study of the HIV Resistance Preceptorship Archived 23 August 2022 at the Wayback Machine ", University of California, Berkeley, 2003.
  46. ↑ Crimmins MT, King BW (June 1996). "An Efficient Asymmetric Approach to Carbocyclic Nucleosides: Asymmetric Synthesis of 1592U89, a Potent Inhibitor of HIV Reverse Transcriptase". The Journal of Organic Chemistry. 61 (13): 4192–4193. doi:10.1021/jo960708p. PMID   11667311.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.